These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 29343652

  • 1. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 2. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, Hirota K, Ueda Y, Kanai Y, Yamashita Y, Kondo E, Sone M, Yasoda A, Inagaki N.
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [Abstract] [Full Text] [Related]

  • 3. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 4. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Aug; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 5. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N, Kobayashi M, Ohashi K, Ito R, Ikeda Y, Kawaguchi G, Yoneoka Y, Hasegawa G, Takada T.
    J Med Case Rep; 2019 Mar 26; 13(1):88. PubMed ID: 30909965
    [Abstract] [Full Text] [Related]

  • 6. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.
    Munakata W, Ohashi K, Yamauchi N, Tobinai K.
    Int J Hematol; 2017 Mar 26; 105(3):383-386. PubMed ID: 27696192
    [Abstract] [Full Text] [Related]

  • 7. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
    Miyoshi Y, Ogawa O, Oyama Y.
    Tohoku J Exp Med; 2016 Jun 26; 239(2):155-8. PubMed ID: 27297738
    [Abstract] [Full Text] [Related]

  • 8. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M.
    J Oncol Pharm Pract; 2020 Jan 26; 26(1):236-239. PubMed ID: 30955467
    [Abstract] [Full Text] [Related]

  • 9. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
    Sakaguchi C, Ashida K, Yano S, Ohe K, Wada N, Hasuzawa N, Matsuda Y, Sakamoto S, Sakamoto R, Uchi H, Furue M, Nomura M, Ogawa Y.
    Curr Oncol; 2019 Feb 26; 26(1):e115-e118. PubMed ID: 30853818
    [Abstract] [Full Text] [Related]

  • 10. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
    O'Malley G, Lee HJ, Parekh S, Galsky MD, Smith CB, Friedlander P, Yanagisawa RT, Gallagher EJ.
    Endocr Pract; 2017 Oct 26; 23(10):1223-1231. PubMed ID: 29045188
    [Abstract] [Full Text] [Related]

  • 11. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, Kakuma T, Shibata H.
    J Diabetes Investig; 2016 Nov 26; 7(6):915-918. PubMed ID: 27181090
    [Abstract] [Full Text] [Related]

  • 12. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I, Capel I, Giménez-Palop O, Albert L, Berges I, Luchtenberg F, García Y, Fernández-Morales LA, De Pedro VJ, Caixàs A, Rigla M.
    J Endocrinol Invest; 2019 Dec 26; 42(12):1443-1450. PubMed ID: 31093955
    [Abstract] [Full Text] [Related]

  • 13. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
    Okiyama N, Tanaka R.
    Nihon Rinsho Meneki Gakkai Kaishi; 2017 Dec 26; 40(2):95-101. PubMed ID: 28603207
    [Abstract] [Full Text] [Related]

  • 14. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
    Hatakeyama Y, Ohnishi H, Suda K, Okamura K, Shimada T, Yoshimura S.
    J Oncol Pharm Pract; 2019 Dec 26; 25(8):2023-2026. PubMed ID: 30526346
    [Abstract] [Full Text] [Related]

  • 15. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
    Matsuura N, Koh G, Konishi C, Minamino S, Takahara Y, Harada H, Kodama K, Emoto M.
    Cancer Immunol Immunother; 2018 Sep 26; 67(9):1417-1424. PubMed ID: 29995236
    [Abstract] [Full Text] [Related]

  • 16. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S, Kuriyama A, Tachibana H.
    J Emerg Med; 2021 Mar 26; 60(3):342-344. PubMed ID: 33097350
    [Abstract] [Full Text] [Related]

  • 17. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
    Yamamoto N, Tsurutani Y, Katsuragawa S, Kubo H, Sunouchi T, Hirose R, Hoshino Y, Ichikawa M, Takiguchi T, Yukawa H, Arioka H, Saitou J, Nishikawa T.
    Intern Med; 2019 Oct 01; 58(19):2825-2830. PubMed ID: 31243198
    [Abstract] [Full Text] [Related]

  • 18. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T.
    Front Endocrinol (Lausanne); 2024 Oct 01; 15():1407192. PubMed ID: 38841300
    [Abstract] [Full Text] [Related]

  • 19. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
    Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L, Madelaine-Chambrin I, Bagot M, Basset-Seguin N, Pages C, Mourah S, Boudou P, Lebbé C, Gautier JF.
    Cancer Immunol Immunother; 2017 Nov 01; 66(11):1399-1410. PubMed ID: 28634815
    [Abstract] [Full Text] [Related]

  • 20. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma.
    Yamaguchi H, Miyoshi Y, Uehara Y, Fujii K, Nagata S, Obata Y, Kosugi M, Hazama Y, Yasuda T.
    Diabetol Int; 2021 Apr 01; 12(2):234-240. PubMed ID: 33786278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.